Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Pfizer is laying off employees across its manufacturing facilities in Ireland, including at Grange Castle, Ringaskiddy and Newbridge. The workforce cuts will start in the last quarter of this year and will continue into next year, the company confirmed to Endpoints News in an email. No further details were given.
Baxter Pharmaceuticals has closed it North Cove facility in Marion, NC, due to Hurricane Helene causing “excessive” rain and flooding damage. The company is working to get the site back up and running, and its utilizing the rest of its manufacturing network to try and mitigate any potential supply issues. While the full impact of the site closure has yet to be seen, this will have a “negative” impact on the company’s annual revenue, Baxter said in a release on Sunday.
Recipharm announced on Thursday it’s expanding its clinical and commercial pharmaceutical development and manufacturing offerings. The CDMO is expanding its small molecule site in Bengaluru, India, by adding a lab for developing sterile products. The company has also added a manufacturing line at its Wasserburg, Germany, site and has expanded its site in Kaysersberg, France. No financial details were disclosed.
Recipharm also partnered with US-based CDMO Exela Pharma Sciences this week, to expand sterile manufacturing offerings in the US, the company said on Tuesday. The new partnership will give Recipharm access to Exela’s factory in Lenoir, NC, which houses abilities in manufacturing sterile injectables in vials and pre-filled syringes.
India-based CDMO Piramal Pharma Solutions is investing $80 million to expand its sterile injectable facility in Lexington, KY, the company said on Monday. The expansion will add 24,000 square feet of capacity, including a new laboratory and manufacturing space. The expansion is anticipated to be finished in the first quarter of 2027.
Bill and Melinda Gates Foundation-backed TerraPower Isotopes is now commercially producing the radioisotope Actinium-225 , the company announced on Tuesday.
California-based SK pharmteco is injecting $260 million to build a new small molecule and peptide manufacturing facility in Sejong, South Korea, the company said on Sunday. The 135,800 square-foot facility will house R&D facilities as well as clinical and commercial manufacturing capabilities. Operations are anticipated to start in late 2026.
Radioisotope producer Nusano has raised over $115 million in a Series C funding round, the company said on Tuesday. The raise will be used to help the company launch new products, including non-carrier-added lutetium-177 and actinium-225.
BioCryst Pharmaceuticals has been awarded a $69 million contract from the US Department of Health and Human Services, according to a Monday announcement. Under the new contract, BioCryst will supply up to 95,625 doses of its flu vaccine, Rapivab, to the US government’s national stockpile over five years.
Cell therapy CDMO Excellos has been chosen by Galapagos to make its CAR-T cell therapy asset, dubbed GLPG5101, for a Phase 1/2 clinical trial in patients with relapsed or refractory non-Hodgkin lymphoma. Excellos will make the candidate at its site in San Diego, CA, according to the Tuesday press release.
Ferring Pharmaceuticals has opened a new 25,000 square-meter manufacturing site in Kuopio, Finland, which will make drug substances for its gene therapy Adstiladrin, a treatment for patients with non-muscle invasive bladder cancer, the company said on Thursday.
Ginkgo Bioworks and Virica Biotech are partnering to reduce the cost of manufacturing gene therapies, the companies said on Thursday. Both companies are providing and integrating their gene therapy manufacturing platforms to offer a combined service to customers.